Pharvaris (PHVS) Q2 2026 earnings summary

Executive summary

• Advanced deucrictibant IR toward regulatory approval, with NDA under FDA review and MAA validated by EMA in July 2026.

• Topline data from pivotal Phase 3 CHAPTER-3 study for deucrictibant XR in HAE prophylaxis expected in 3Q2026.

• Enrollment ongoing in pivotal studies for both HAE and AAE-C1INH, including CREAATE and CHAPTER-4.

• Expanded Access Program for deucrictibant IR launched in the U.S. for eligible HAE patients.

• Promoted Dr. Peng Lu to President, consolidating R&D and commercial leadership.

Financial highlights

• Cash and cash equivalents stood at €318 million as of June 30, 2026, up from €292 million at year-end 2025.

• R&D expenses were €35.0 million for Q2 2026, compared to €29.6 million in Q2 2025.

• G&A expenses were €15.8 million for Q2 2026, up from €10.8 million in Q2 2025.

• Net loss for Q2 2026 was €47.8 million, or €0.70 per share, compared to €45.5 million, or €0.83 per share, in Q2 2025.

• Closed $132 million underwritten offering in May, extending cash runway into 2028.

Outlook and guidance

• Topline data from CHAPTER-3 Phase 3 study expected in Q3 2026.

• FDA PDUFA date for deucrictibant IR NDA set for April 23, 2027.

• Cash runway extended into 2028, supporting pre-commercial and lifecycle management activities.